FocalTherics (FOCL) Q3 2026 earnings review
FocalTherics procedure volumes climb fast, but delayed machine sales cut its outlook
FocalTherics, a maker of robotic ultrasound machines for prostate surgery, saw hospital procedure volumes climb while delayed equipment purchases weighed on quarterly revenue. Sales grew 26% from a year ago and gross margin expanded nearly 5 percentage points on higher pricing, though operating losses widened. Chief executive Ryan Rhodes said three hospital machine deals slipped past the quarter's close, prompting the company to trim the top of its full-year sales plan. By our math, the updated plan points to fourth-quarter revenue growth slowing to about 21%.
| Revenue | $9.8M +26% from a year ago |
|---|---|
| US procedure volume | +32% +15% a year ago |
| Gross margin | 51.4% 46.6% a year ago |
| Full-year revenue outlook | Cut $1M at middle range narrowed to $50–52M |
⚖️ Verdict: 🔴 Bearish
The story got worse because holding the full-year outlook in the first half turned out to reflect real second-half equipment delays rather than management caution. Even though management expects all three delayed machines to book in the fourth quarter, it still cut $2 million off the top of its annual target, while quarterly cash burn stayed above $5 million by our math. The bright spot is that doctors are using the installed machines more often, with US procedures up 32% and major insurers adding coverage for recurring prostate cancer.
The question now is whether the lower annual ceiling reflects simple caution after a late bank approval or a broader slowdown in hospital equipment budgets. If fourth-quarter orders are healthy, adding the three delayed machines should push full-year sales to the top of the $50 million to $52 million range; if hospital committees keep stalling, sales will land near the bottom. Fourth-quarter machine placements will settle it.
🐂 Bull Case
US Procedures And Payer Coverage Keep Expanding
FocalTherics makes Focal One, a robotic machine that uses high-intensity focused ultrasound (HIFU) to destroy prostate tissue without invasive surgery. Each procedure requires a single-use disposable probe, so rising treatment volumes bring steady recurring sales even when hospital machine purchases stall. In the third quarter, US procedure volumes rose 32% from a year ago, and total treatment-driven revenue grew 24%.
That 32% volume gain slowed from 47% in the second quarter, because the company compared against 15% growth a year ago rather than the 4% to 5% base from the first half of 2025. Commercial insurance access also widened for men whose prostate cancer returns after radiation. Following a clinical guideline upgrade, Aetna, Cigna, Humana, United and several Blue Cross plans issued positive coverage policies over the past eight months, chief executive Ryan Rhodes said.
What to watch: fourth-quarter US procedure growth against a tougher 28% comparison from a year ago, and first-time disclosure of international procedure growth in 2027. Holding US procedure growth near 30% in the busiest quarter of the year would show that established hospital programs and new salvage coverage can offset lumpier machine sales.
Better Machine Pricing Lifted Gross Margin
FocalTherics wants its standalone ultrasound business to earn software-like product margins as it winds down its older stone-breaking and distribution units. Third-quarter gross margin reached 51.4%, up 4.8 percentage points from 46.6% a year ago, as cost of sales fell from 53.4% of revenue to 48.6%. The medical device maker credited the improvement to "improvement on standard cost of the Focal One and higher average selling price of our Focal One systems and Focalpaks", which are its single-use procedure kits.
Gross margin stepped down from 55.6% in the second quarter because the group sold seven machines instead of thirteen, leaving less revenue to cover fixed factory overhead. Even with that seasonal dip in machine deliveries, keeping gross margin above 51% shows that unit pricing and manufacturing cost reductions are holding.
What to watch: fourth-quarter gross margin when machine deliveries rebound for the year-end hospital buying season. A return to the mid-50% range would confirm that the third-quarter dip came only from lower seasonal volume.
Repeat Hospital Buyers And New Uses Grow
A core part of the Pure-play Focal One pitch is that large health networks buy additional machines once their first unit fills up, while new medical uses expand the market beyond prostate cancer. In the third quarter, Baylor Scott & White Health bought its second system, bringing the number of US hospital networks with two or more machines to 16, up from 15 last quarter. Kaiser Permanente also leased two more machines in California, raising its total to four.
Outside prostate cancer, three European hospitals — two in France and one in Hungary — now treat paying patients for deep infiltrating endometriosis, a painful condition where uterine-like tissue grows on pelvic organs. Doctors from additional hospitals in the UK and France are currently training to offer the procedure, Rhodes said.
What to watch: publication of the randomized clinical trial for endometriosis and the Phase 3 HIFUSA prostate trial, which Rhodes expects early next year. Those peer-reviewed studies are required to move new uses from small European launches toward US regulatory clearance and insurance coverage.
🐻 Bear Case
Delayed Machine Sales Forced A Lower Outlook
"Our third quarter revenues were adversely affected by deal timing challenges," chief executive Ryan Rhodes said. FocalTherics sold seven Focal One machines in the quarter compared to six a year ago, because three expected hospital deals slipped past the September cutoff. Finance chief Ken Mobeck said one customer's purchase got held up at a financing bank and hospital approval committees moved slowly over the summer, adding that "the three systems that we had anticipated in the third quarter are now forecasted to revenue in the fourth quarter."
Rhodes said the company already closed one of those delayed sales in the fourth quarter and signed purchase orders for the other two. However, if all three deals simply shifted from the third quarter into the fourth, full-year revenue would not change. Instead, management cut the top end of its 2026 revenue plan by $2 million to a range of $50 million to $52 million. By our math, the middle of that new plan implies fourth-quarter revenue growth of 21.2%, down from 55% in the first half and 25.5% in the third quarter.
What to watch: fourth-quarter equipment revenue against the $16.4 million total revenue implied by the middle of the full-year outlook. A result near that level would mean fourth-quarter orders merely replaced the delayed third-quarter deals rather than adding on top of them.
Operating Losses And Cash Burn Keep Growing
Headline net loss looked smaller this quarter at $4.5 million versus $5.9 million a year ago, but an accounting gain on European Investment Bank warrants created that improvement. Excluding the $2.6 million non-cash warrant gain, loss from continuing operations was $7.9 million by our math. Operating loss widened to $7.8 million from $6.7 million a year ago because selling, general and administrative expenses rose 3.2 percentage points of revenue to 105.5%, driven by "incremental headcount-related compensation costs including higher stock-based compensation, and additional sales and marketing expenses related to various Urology meetings and events".
- Operating loss: $7.8 million, compared to $6.7 million a year ago
- Selling and administrative expenses: $10.4 million, or 105.5% of revenue, up from 102.4% a year ago
- Corporate overhead not tied to ultrasound: $1.6 million, up from $1.3 million a year ago
- Third-quarter free cash flow: -$5.4 million by our math, bringing nine-month cash burn to $14.0 million
What to watch: fourth-quarter selling and administrative expenses as a share of revenue. If seasonal peak sales of $16 million to $17 million do not bring operating losses down, the $56.3 million cash balance will fund less than three years of operations.
Risks this quarter didn't answer
Four standing concerns from prior quarters received no concrete updates in the third-quarter release or conference call.
- Sale of discontinued businesses: management gave no update on a buyer or price for the stone-breaking and distribution units, which must be sold by mid-2027 under the company's plan.
- US benign prostate trial: Rhodes mentioned ongoing work in Chile with Mount Sinai doctors, but did not confirm whether the first US patient in New York has been treated as planned for late 2026.
- 2027 Medicare hospital payment rate: management did not say whether the final government rule confirmed the proposed 11.6% increase to $10,797 per procedure.
- Import tariffs: the release and call gave no figure for tariff costs on machines shipped from France to the US.
💲 Other KPIs
Cash more than doubled from $21.5 million at the end of June after FocalTherics completed an equity offering in August. That raise brought nine-month financing cash inflows to $50.7 million, though it also pushed the average share count up 13.9% from a year ago to 42.6 million shares.
Combined current and long-term deferred revenue — cash customers have paid for service contracts and leases not yet delivered — rose 12.4% from last quarter and 13.9% from the end of 2025 by our math. That steady rise tracks the expanding base of 192 installed machines.
🔮 Guidance
Cut at the top end. Management trimmed $2 million from the upper bound after holding the $50 million to $54 million range for three straight quarters, lowering the middle of the plan to 36.5% growth. By our math, that leaves $15.4 million to $17.4 million for the fourth quarter, or 21.2% growth at the middle of the range — the slowest pace of the year.
❓ Key Questions
Why did three delayed deals cut the full-year ceiling?
Management said all three delayed third-quarter machines will book in the fourth quarter, with one already closed and two under purchase orders. If those sales shifted into the fourth quarter without displacing fourth-quarter pipeline deals, why did the full-year ceiling drop by $2 million?
Have the first US benign prostate patients been treated?
Last quarter management planned to treat the first US patients in its benign prostatic hyperplasia (BPH) study at Mount Sinai in New York before year-end. This quarter's remarks mentioned only the ongoing study in Chile.
Where do talks stand on selling the discontinued units?
The stone-breaking and distribution businesses were classified as held for sale in May 2026 with a one-year window to close a deal. Management has not yet named a buyer, a timeline, or whether sale proceeds must repay European Investment Bank debt.
When will the endometriosis clinical trial paper be published?
Publishing the completed randomized trial for endometriosis was expected before the end of 2026 and is a required step before the next US Food and Drug Administration meeting.